Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of September 23, 2024
Click Here to Manage Email Alerts
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.
Read the full coverage here:
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Infliximab biosimilar uptake rapidly increased only after release of a third option
National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala
Safety checklist compiles clinically important DMARD warnings in one place
Guselkumab demonstrates long-term efficacy, safety in psoriasis
References:
Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.
Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.
Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.
Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.
Collapse
Click Here to Manage Email Alerts
